Oncimmune Holdings (LSE:ONC) Debt-to-EBITDA : -4.36 (As of Feb. 2024)

Oncimmune Holdings Debt-to-EBITDA Chart

Oncimmune Holdings Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	Aug23
Debt-to-EBITDA		Get a 7-Day Free Trial					-	-0.92	-2.11	-1.49	-1.20

Oncimmune Holdings Semi-Annual Data
	May14	Nov14	May15	Nov15	May16	Nov16	May17	Nov17	May18	Nov18	May19	Nov19	May20	Nov20	May21	Nov21	May22	Feb23	Aug23	Feb24
Debt-to-EBITDA	Get a 7-Day Free Trial															-1.13	-1.55	-1.94	-1.53	-4.36

Competitive Comparison of Oncimmune Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, Oncimmune Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncimmune Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Debt-to-EBITDA falls into.

Oncimmune Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oncimmune Holdings's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Oncimmune Holdings's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Feb. 2024) EBITDA data.

Oncimmune Holdings  (LSE:ONC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Oncimmune Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncimmune Holdings Business Description